Psychiatry drugs finally have pharma's attention. Can they keep it?

BioPharma

Related Keywords

Mizuho ,Hokkaido ,Japan ,Boston ,Massachusetts ,United States ,Germany ,Japanese ,German ,Sumitomo Pharma ,Andrew Miller ,Paul Matteis ,Paul Kenny ,Bristol Myers ,Mitzi Gonzales ,Bristol Myer Hargreaves ,Alex Beckett ,Daphne Zohar ,Joseph Vu ,Jose Luis Calvin Martin ,Eli Lilly ,Graig Suvannavejh ,Jose Enrique Garcia Maurino Muzquiz ,Jeffrey Lieberman ,David Feinberg ,Neurocrine Biosciences ,Richard Hargreaves ,Columbia University Medical Center ,Johnson ,Drug Administration ,Boehringer Ingelheim ,Alkermes ,Bristol Myers Squibb ,Cantor Fitzgerald ,Puretech Health ,Jazz Pharmaceuticals ,Karuna Therapeutics ,Wall Street ,Cerevel Therapeutics ,Drug Discovery Institute ,Mount Sinai ,Icahn School ,Luis Calvin Martin ,Mizuho Securities ,Carol Lim ,Massachusetts General ,Neumora Therapeutics ,Maplight Therapeutics ,Takeda Pharmaceutical ,Otsuka Pharmaceutical ,Lykos Therapeutics ,Myer Hargreaves ,Intra Cellular Therapies ,Acadia Pharmaceutical ,Pharma ,Biotech ,